US Stock MarketDetailed Quotes

ANIP ANI Pharmaceuticals

Watchlist
  • 58.460
  • +0.960+1.67%
Close Jan 17 16:00 ET
  • 58.210
  • -0.250-0.43%
Pre 06:08 ET
1.23BMarket Cap-124.38P/E (TTM)

ANI Pharmaceuticals Key Stats

ANI Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 166.696M--
--2024/Q4-- / 175.388M--
Nov 8, 20242024/Q3148.332M / 144.375M--
Aug 6, 20242024/Q2138.040M / 129.053M--
May 10, 20242024/Q1137.430M / 126.028M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 166.696M--
--2024/Q4-- / 175.388M--
Nov 8, 20242024/Q3148.332M / 144.375M--
Aug 6, 20242024/Q2138.040M / 129.053M--
May 10, 20242024/Q1137.430M / 126.028M--

Unlock Free Earnings Estimates

ANI Pharmaceuticals Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 20, 2025

Strong Buy

  • Buy

    75.00%
  • Hold

    25.00%
  • Sell

    0.00%

Price Target

No Data